3.28
price up icon9.70%   0.29
after-market Handel nachbörslich: 3.24 -0.04 -1.22%
loading
Schlusskurs vom Vortag:
$2.99
Offen:
$3.01
24-Stunden-Volumen:
192.91K
Relative Volume:
3.00
Marktkapitalisierung:
$48.38M
Einnahmen:
$486.00K
Nettoeinkommen (Verlust:
$-28.43M
KGV:
-0.2971
EPS:
-11.04
Netto-Cashflow:
$-26.75M
1W Leistung:
+21.93%
1M Leistung:
+73.54%
6M Leistung:
+25.19%
1J Leistung:
+8.25%
1-Tages-Spanne:
Value
$2.96
$3.30
1-Wochen-Bereich:
Value
$2.57
$3.30
52-Wochen-Spanne:
Value
$1.57
$4.4808

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
Firmenname
Vyne Therapeutics Inc
Name
Telefon
800-775-7936
Name
Adresse
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
Mitarbeiter
10
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
VYNE's Discussions on Twitter

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-12-06 Fortgesetzt H.C. Wainwright Buy

Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten

pulisher
Oct 09, 2024

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St

Oct 09, 2024
pulisher
Sep 26, 2024

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance

Sep 26, 2024
pulisher
Sep 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

(VYX) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha

Sep 23, 2024
pulisher
Sep 23, 2024

Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World

Sep 23, 2024
pulisher
Sep 20, 2024

Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily

Sep 19, 2024
pulisher
Sep 14, 2024

HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Sep 12, 2024
pulisher
Sep 03, 2024

VYNE Therapeutics to Participate in September Investor Conferences - StockTitan

Sep 03, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics sees cash runway through end of 2025 - TipRanks

Aug 17, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Aug 16, 2024
pulisher
Aug 15, 2024

VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks

Aug 15, 2024
pulisher
Aug 14, 2024

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Aug 14, 2024
pulisher
Aug 14, 2024

VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace

Aug 14, 2024
pulisher
Aug 08, 2024

Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Aug 08, 2024
pulisher
Jul 24, 2024

VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World

Jul 24, 2024
pulisher
Jul 21, 2024

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St

Jul 21, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics secures UK patent for inflammation drug - Investing.com

Jul 16, 2024
pulisher
Jul 16, 2024

Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC

Jul 16, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Jul 16, 2024
pulisher
Jul 11, 2024

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance

Jul 11, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz

Jul 09, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan

Jul 09, 2024
pulisher
Jul 05, 2024

How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia

Jul 05, 2024
pulisher
Jul 04, 2024

VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St

Jul 04, 2024
pulisher
Jul 03, 2024

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times

Jul 03, 2024
pulisher
Jun 30, 2024

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World

Jun 30, 2024
pulisher
Jun 28, 2024

Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow

Jun 28, 2024
pulisher
Jun 26, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan

Jun 26, 2024
pulisher
Jun 26, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.

Jun 26, 2024
pulisher
Jun 18, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK

Jun 18, 2024
pulisher
Jun 16, 2024

Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 16, 2024
pulisher
Jun 14, 2024

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India

Jun 14, 2024
pulisher
Jun 14, 2024

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada

Jun 14, 2024
pulisher
Jun 14, 2024

VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World

Jun 14, 2024
pulisher
Jun 14, 2024

Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga

Jun 14, 2024
pulisher
Jun 13, 2024

Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times

Jun 13, 2024
pulisher
Jun 13, 2024

VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Jun 13, 2024

Finanzdaten der Vyne Therapeutics Inc-Aktie (VYNE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):